Acromegaly Update podcast

Acromegaly Update — Monday September 21, 2026

0:00
7:00
Rewind 15 seconds
Fast Forward 15 seconds
This week's acromegaly literature centers on long-term disease burden — cardiovascular morbidity, musculoskeletal disease, and precision-medicine treatment selection — while the rare disease industry notched a landmark ultra-rare gene therapy approval, a $1.65B radiopharma merger, and a $123M bet on an oral thyroid eye disease pill.

More episodes from "Acromegaly Update"